January 25, 2018/Neurosciences/Research

Comprehensive Vs. Primary Stroke Centers: Is There a Quality Difference?

CSCs achieve timelier acute reperfusion therapy, national study finds

Streamlined STEMI Protocol Slashes Door-to-Balloon Times

Do Comprehensive Stroke Centers really offer an advantage over Primary Stroke Centers in providing patient care?

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

According to a large new national study of stroke centers, the answer is yes, at least on a few key measures, although overall stroke care was found to be broadly similar between the two certification levels. The study was presented at the 2018 International Stroke Conference in Los Angeles. (Editor’s note: The full study was published online by Circulation: Cardiovascular Quality and Outcomes on May 23, 2018.)

“Determining whether Comprehensive Stroke Centers offer an advantage and, if so, how much of one, is important for allocating resources to optimize patient care,” says Ken Uchino, MD, Director of Research and Education for Cleveland Clinic’s Cerebrovascular Center and a co-author of the multicenter study. “Does every community need a Comprehensive Stroke Center? Does every patient with an acute stroke need to be referred to one? Such questions are worth investigating.”

The certifications at a glance

To briefly define terms, The Joint Commission provides certification to hospitals that meet standards recommended by the Brain Attack Coalition for care of acute stroke. Since 2012, two levels of certification have been offered: Primary Stroke Centers (PSCs) and Comprehensive Stroke Centers (CSCs), with the latter designation requiring an ability to provide more-complex services, including 24/7 availability of endovascular procedures.

Study design

Investigators with the current study used the American Heart Association/American Stroke Association’s Get With The Guidelines®–Stroke database to identify consecutive patients with a final diagnosis of acute ischemic stroke who were admitted to 134 CSCs (110,624 patients) and 1,047 PSCs (494,512 patients) between January 1, 2013, and December 31, 2015.

Multivariable regression analysis was done to explore associations between facilities’ certification level and performance measures and outcomes, after adjustment for potential confounding variables.

Advertisement

Key findings

CSCs were noted to be larger than PSCs, with median bed counts of 481 versus 263, respectively.

Almost all hospitals in both groups (94 percent) were found to conform with seven key performance measures, including intravenous thrombolysis among those arriving within two hours of symptom onset; use of antithrombotic medication and deep vein thrombosis prophylaxis in appropriate patients; discharge medications for atrial fibrillation and lipid lowering when indicated; and addressing smoking cessation.

However, CSCs outperformed PSCs in several key measures, especially in the use of intravenous tissue plasminogen activator (IV tPA) and intra-arterial thrombectomy (IA therapy). Among the significant differences:

  • IV tPA was administered to 14.3 percent of patients in CSCs versus 10.3 percent in PSCs (adjusted odds ratio [OR] = 1.23; 95% CI, 1.12-1.34).
  • Time from door to delivery of IV tPA was within one hour in 79.7 percent of patients in CSCs versus 65.1 percent in PSCs (adjusted OR = 1.48; 95% CI, 1.25-1.75).
  • Median time from door to IV tPA was 52 minutes in CSCs versus 61 minutes in PSCs (adjusted OR = 0.92; 95% CI, 0.89-0.95).
  • IA therapy was provided in 4.1 percent of patients in CSCs versus 1.0 percent in PSCs (adjusted OR = 2.35; 95% CI, 1.82-3.04).
  • Median time from door to IA therapy was 145 minutes in CSCs versus 152 minutes in PSCs (adjusted OR = 0.92; 95% CI, 0.87-0.98).

“We observed that CSCs are slightly but significantly better at providing prompt acute treatment,” says Dr. Uchino. “But overall, stroke care is similar between CSCs and PSCs, and both types of facilities are achieving good quality process measures.”

Data hide nuances

Dr. Uchino notes that there are many complexities in doing a study such as this one. Some PSCs are actually equivalent to CSCs but for various reasons have not pursued the higher certification. Others may provide thrombectomy (one of the key differences between the certification levels) but are missing other elements believed to be less critical. Such issues potentially confound the data by blurring differences between the two types of facilities.

Advertisement

Interestingly, the study found that in-hospital mortality was modestly higher at CSCs than at PSCs, even after adjusting for patient comorbidities (4.6 percent versus 3.8 percent; adjusted OR = 1.14; 95% CI, 1.01-1.29). According to Dr. Uchino, the current study cannot account for this difference, and he suspects other unmeasured variables may offer an explanation since it’s unlikely that the higher level of care measures at CSCs found in the study led to more deaths.

“It is critical for facilities to be transparent about their outcomes by collecting data on their performance measures and making them available for investigation and comparison,” he adds. “This is the only way we can determine if initiatives such as acute stroke care certification are important and how to further improve patient outcomes.”

Cleveland Clinic’s main campus hospital is a Joint Commission-certified Comprehensive Stroke Center. Cleveland Clinic health system also includes seven Primary Stroke Centers.

Related Articles

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

22-NEU-2959102-CQD-Hero-650×450
June 15, 2022/Neurosciences/Research
MINDS Study Will Assess Lifestyle Interventions for Slowing Brain Pathology in Preclinical Stages

New grant-funded investigation illustrates impact and reach of Cleveland Clinic Brain Study

22-NEU-2671014-CQD-650×450-Type
March 9, 2022/Neurosciences/Research
A Closer Look at the Cleveland Clinic Brain Study

How the new longitudinal investigation could become the Framingham Heart Study of brain health

20-NEU-1959738 powered-exoskeleton-for-gait-training_650x450
October 23, 2020/Neurosciences/Research
Study Signals Potential of Powered Exoskeleton for Gait Training in Multiple Sclerosis

Pilot findings show good patient acceptance and safety, early hints of efficacy

20-NEU-1990660-sleep-symptoms-in-health-workers-650×450
October 21, 2020/Neurosciences/Research
Electronic Screening for Sleep Disorders Among Healthcare Workers Is Feasible – and Sorely Needed

Study finds high prevalence of symptoms, willingness to seek treatment

20-NEU-1946228 neurofilaments_650x450
September 9, 2020/Neurosciences/Research
Serum Neurofilament Light as a Progressive MS Biomarker: Guideposts for the Road Ahead

Panel outlines research priorities around a promising alternative to imaging markers

20-NEU-1951118_Impella-temporary-LVAD_650x450_ (1)
September 4, 2020/Neurosciences/Research
Study Finds Clues to Acute Neurologic Events With Short-Term Impella Cardiac Support

Suspected factors include antithrombotic intensity, time on device, presence of thrombocytopenia

20-NEU-1929179 deep-brain-stimulation-for-TBI_650x450
September 3, 2020/Neurosciences/Research
Could DBS of the Cerebellar Dentate Nucleus Enhance Post-TBI Rehabilitation?

Preclinical studies will assess whether method developed for stroke recovery curbs deficits after brain injury

Ad